Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Beckert, Patrick![]() |
|
dc.contributor.author | Sanchez-Padilla, Elisabeth![]() |
|
dc.contributor.author | Merker, Matthias![]() |
|
dc.contributor.author | Dreyer, Viola![]() |
|
dc.contributor.author | Kohl, Thomas A.![]() |
|
dc.contributor.author | Utpatel, Christian![]() |
|
dc.contributor.author | Köser, Claudio U.![]() |
|
dc.contributor.author | Barilar, Ivan![]() |
|
dc.contributor.author | Ismail, Nazir Ahmed![]() |
|
dc.contributor.author | Omar, Shaheed Vally![]() |
|
dc.contributor.author | Klopper, Marisa![]() |
|
dc.contributor.author | Warren, Robin M.![]() |
|
dc.contributor.author | Hoffmann, Harald![]() |
|
dc.contributor.author | Maphalala, Gugu![]() |
|
dc.contributor.author | Ardizzoni, Elisa![]() |
|
dc.contributor.author | De Jong, Bouke C.![]() |
|
dc.contributor.author | Kerschberger, Bernhard![]() |
|
dc.contributor.author | Schramm, Birgit![]() |
|
dc.contributor.author | Andres, Sonke![]() |
|
dc.contributor.author | Kranzer, Katharina![]() |
|
dc.contributor.author | Maurer, Florian P.![]() |
|
dc.contributor.author | Bonnet, Maryline![]() |
|
dc.contributor.author | Niemann, Stefan![]() |
|
dc.date.accessioned | 2021-04-14T12:04:33Z | |
dc.date.available | 2021-04-14T12:04:33Z | |
dc.date.issued | 2020-12 | |
dc.description.abstract | BACKGROUND: Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F resistance mutation are threatening the control of MDR tuberculosis (MDR-TB) in Eswatini. METHODS: We investigate the evolution and spread of MDR strains in Eswatini with a focus on bedaquiline (BDQ) and clofazimine (CFZ) resistance using whole-genome sequencing in two collections ((1) national drug resistance survey, 2009–2010; (2) MDR strains from the Nhlangano region, 2014–2017). RESULTS: MDR strains in collection 1 had a high cluster rate (95%, 117/123 MDR strains) with 55% grouped into the two largest clusters (gCL3, n = 28; gCL10, n = 40). All gCL10 isolates, which likely emerged around 1993 (95% highest posterior density 1987–1998), carried the mutation RpoB I491F that is missed by commercial mDST assays. In addition, 21 (53%) gCL10 isolates shared a Rv0678 M146T mutation that correlated with elevated minimum inhibitory concentrations (MICs) to BDQ and CFZ compared to wild type isolates. gCL10 isolates with the Rv0678 M146T mutation were also detected in collection 2. CONCLUSION: The high clustering rate suggests that transmission has been driving the MDR-TB epidemic in Eswatini for three decades. The presence of MDR strains in Eswatini that are not detected by commercial mDST assays and have elevated MICs to BDQ and CFZ potentially jeopardizes the successful implementation of new MDR-TB treatment guidelines. Measures to limit the spread of these outbreak isolates need to be implemented urgently. | en_ZA |
dc.description.department | Medical Microbiology | en_ZA |
dc.description.librarian | pm2021 | en_ZA |
dc.description.sponsorship | The European Union TB-PAN-NET (FP7-223681) project, by Médecins Sans Frontières-Switzerland, and by German Center for Infection Research, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy – EXC 2167, and Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). | en_ZA |
dc.description.uri | http://genomemedicine.com | en_ZA |
dc.identifier.citation | Beckert, P., Sanchez-Padilla, E., Merker, M. et al. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. Genome Medicine 12, 104 (2020). https://doi.org/10.1186/s13073-020-00793-8. | en_ZA |
dc.identifier.issn | 1756-994X (online) | |
dc.identifier.other | 10.1186/s13073-020-00793-8 | |
dc.identifier.uri | http://hdl.handle.net/2263/79446 | |
dc.language.iso | en | en_ZA |
dc.publisher | BioMed Central | en_ZA |
dc.rights | © The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License. | en_ZA |
dc.subject | Resistance evolution | en_ZA |
dc.subject | MDR outbreak strains | en_ZA |
dc.subject | Diagnostice escape | en_ZA |
dc.subject | Treatment escape | en_ZA |
dc.subject | Treatment failure | en_ZA |
dc.subject | Tuberculosis (TB) | en_ZA |
dc.subject | Multidrug resistant (MDR) | en_ZA |
dc.subject | Molecular drug susceptibility testing (mDST) | en_ZA |
dc.subject | MDR tuberculosis (MDR-TB) | en_ZA |
dc.subject | Minimum inhibitory concentration (MIC) | en_ZA |
dc.title | MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era | en_ZA |
dc.type | Article | en_ZA |